Updated TDP-43 in Alzheimer’s disease staging scheme

Acta Neuropathologica

Volumn 131, Issue 4, 2016, Pages 571-585

  Josephs, Keith A ^a   Murray, Melissa E ^b   Whitwell, Jennifer L ^a   Tosakulwong, Nirubol ^a   Weigand, Stephen D ^a   Petrucelli, Leonard ^b   Liesinger, Amanda M ^b   Petersen, Ronald C ^a   Parisi, Joseph E ^a   Dickson, Dennis W ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer s disease; Brainstem; Insular cortex; Limbic; Staging; TDP 43

Indexed keywords

TAR DNA BINDING PROTEIN; DNA BINDING PROTEIN; TDP-43 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMNESIA; AMYGDALOID NUCLEUS; APHASIA; ARTICLE; BASAL GANGLION; BOSTON NAMING TEST; CLINICAL FEATURE; DENTATE GYRUS; DISEASE COURSE; ENTORHINAL CORTEX; FEMALE; FOREBRAIN; FRONTOTEMPORAL DEMENTIA; GLOBUS PALLIDUS; HUMAN; INFERIOR OLIVE; INFERIOR TEMPORAL CORTEX; INSULA; MAJOR CLINICAL STUDY; MALE; MEDIAL FRONTAL CORTEX; NEUROPSYCHOLOGICAL TEST; OCCIPITOTEMPORAL CORTEX; PRIORITY JOURNAL; PROGRESSIVE NONFLUENT APHASIA; PUTAMEN; SUBICULUM; SUBSTANTIA NIGRA; TECTUM; TEMPORAL CORTEX; VENTRAL STRIATUM; VERY ELDERLY; BRAIN; COHORT ANALYSIS; DIAGNOSTIC IMAGING; MENTAL HEALTH; METABOLISM; MIDDLE AGED; ONSET AGE; PATHOLOGY; PROBABILITY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PROBABILITY;

EID: 84961140252     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1537-1     Document Type: Article

References (44)

1. Aguzzi A, Rajendran L (2009) The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64:783–790. doi:10.1016/j.neuron.2009.12.016
2. Amador-Ortiz C, Lin WL, Ahmed Z et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445. doi:10.1002/ana.21154
3. Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611. doi:10.1016/j.bbrc.2006.10.093
4. Arai T, Mackenzie IR, Hasegawa M et al (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136. doi:10.1007/s00401-008-0480-1
5. Arnold SJ, Dugger BN, Beach TG (2013) TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol 126:51–57. doi:10.1007/s00401-013-1110-0
6. Benton A, Hamsher K (1989) Multilingual aphasia examination. University of Iowa, Iowa City
7. Bigio EH, Mishra M, Hatanpaa KJ et al (2010) TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol 120:43–54. doi:10.1007/s00401-010-0681-2
8. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259
9. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404. doi:10.1007/s00401-006-0127-z
10. Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969. doi:10.1097/NEN.0b013e318232a379
11. Brettschneider J, Del Tredici K, Toledo JB et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20–38. doi:10.1002/ana.23937
12. Clavaguera F, Hench J, Goedert M, Tolnay M (2015) Invited review: prion-like transmission and spreading of tau pathology. Neuropathol Appl Neurobiol 41:47–58. doi:10.1111/nan.12197
13. Davidson Y, Kelley T, Mackenzie IR et al (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113:521–533. doi:10.1007/s00401-006-0189-y
14. Davidson YS, Raby S, Foulds PG et al (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset Alzheimer’s disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 122:703–713. doi:10.1007/s00401-011-0879-y
15. Dickson DW, Braak H, Duda JE et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157. doi:10.1016/S1474-4422(09)70238-8
16. Fahn S, Elton R, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M (eds) Recent developments in Parkinson’s disease, 2nd edn. Macmillan Healthcare Information, Floram Park
17. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
18. Hu WT, Josephs KA, Knopman DS et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 116:215–220. doi:10.1007/s00401-008-0400-4
19. Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16. doi:10.1007/s00401-008-0406-y
20. Josephs KA, Whitwell JL, Knopman DS et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70:1850–1857. doi:10.1212/01.wnl.0000304041.09418.b1
21. Josephs KA, Stroh A, Dugger B, Dickson DW (2009) Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol 118:349–358. doi:10.1007/s00401-009-0547-7
22. Josephs KA, Murray ME, Whitwell JL et al (2014) Staging TDP-43 pathology in Alzheimer’s disease. Acta Neuropathol 127:441–450. doi:10.1007/s00401-013-1211-9
23. Josephs KA, Whitwell JL, Weigand SD et al (2014) TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol 127:811–824. doi:10.1007/s00401-014-1269-z
24. Josephs KA, Whitwell JL, Tosakulwong N et al (2015) TAR DNA-binding protein 43 and pathological subtype of Alzheimer’s disease impact clinical features. Ann Neurol 78:697–709. doi:10.1002/ana.24493
25. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45–51. doi:10.1038/nature12481
26. Jung Y, Dickson DW, Murray ME et al (2014) TDP-43 in Alzheimer’s disease is not associated with clinical FTLD or Parkinsonism. J Neurol 261:1344–1348. doi:10.1007/s00415-014-7352-5
27. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K (2009) Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 29:566–573. doi:10.1111/j.1440-1789.2009.01017.x
28. Kaplan E, Goodglass H, Weintraubb S (1983) The Boston Namiing test. Lea & Febiger, Philadelphia
29. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287:19440–19451. doi:10.1074/jbc.M112.346072
30. Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ (2007) TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol 114:63–70. doi:10.1007/s00401-007-0226-5
31. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E (2010) Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6:702–706. doi:10.1038/nrneurol.2010.145
32. Mattis S (1998) Dementia Rating Scale (DRS). Psychologial Assessment Resources, Odessa
33. Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486
34. Montine TJ, Phelps CH, Beach TG et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11. doi:10.1007/s00401-011-0910-3
35. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414
36. Nag S, Yu L, Capuano AW et al (2015) Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 77:942–952. doi:10.1002/ana.24388
37. Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. doi:10.1126/science.1134108
38. Nonaka T, Masuda-Suzukake M, Arai T et al (2013) Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 4:124–134. doi:10.1016/j.celrep.2013.06.007
39. Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, City
40. Uchino A, Takao M, Hatsuta H et al (2015) Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun 3:35. doi:10.1186/s40478-015-0215-1
41. Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564. doi:10.1097/NEN.0b013e31817713b5
42. Wechsler D (1997) Wechsler Adult Intelligence Scale-III. Physiological Corporation, New York
43. Working group (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18:S1–S2
44. Zhang YJ, Xu YF, Cook C et al (2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA 106:7607–7612. doi:10.1073/pnas.0900688106